Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL)
Authors:
Open Access
- 30 October 2018
- journal article
- research article
- Published by Wiley in Bipolar Disorders
- Vol. 20 (8) , 733-745
Abstract
Objectives: Although not licensed for acute bipolar depression, lamotrigine has evidence for efficacy in trials and its use is recommended in guidelines. So far there had been no prospective health economic evaluation of its use.Methods: Cost‐utility analysis of the CEQUEL trial comparing quetiapine plus lamotrigine vs quetiapine monotherapy (and folic acid vs placebo in an add‐on factorial design) for patients with bipolar depression (n = 201) from the health and social care perspective. Differences in costs together with quality‐adjusted life years (QALYs) between the groups were assessed over 52 weeks using a regression‐based approach.Results: Health‐related quality of life improved substantially for all randomization groups during follow‐up with no significant difference in QALYs between any of the comparisons (mean adjusted QALY difference: lamotrigine vs placebo −0.001 (95% CI: −0.05 to 0.05), folic acid vs placebo 0.002 (95% CI: −0.05 to 0.05)). While medication costs in the lamotrigine group were higher than in the placebo group (£647, P < 0.001), mental health community/outpatient costs were significantly lower (−£670, P < 0.001). Mean total costs were similar in the groups (−£180, P = 0.913).Conclusions: Lamotrigine improved clinical ratings in bipolar depression compared with placebo. This differential effect was not detected using the EQ‐5D‐3L. The additional cost of lamotrigine was balanced by significant savings in some other medical costs which made its use cost neutral to the health service. Compared to placebo, folic acid produced neither clinical nor significant health economic benefits. The study supports the use of lamotrigine in combination with other drugs to treat bipolar depression.Keywords
Funding Information
- Medical Research Council (81651)
This publication has 20 references indexed in Scilit:
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Prescribing Trends in Bipolar Disorder: Cohort Study in the United Kingdom THIN Primary Care Database 1995–2009PLOS ONE, 2011
- Cost of disorders of the brain in Europe 2010European Neuropsychopharmacology, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar DepressionThe Journal of Clinical Psychiatry, 2008
- Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measuresQuality of Life Research, 2006
- Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utilityHealth Economics, 2004
- Folate for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled TrialsJournal of Psychopharmacology, 2004
- Suicidal Behaviour in Bipolar DisorderCNS Drugs, 2003
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990